Iron deficiency anemia Medical Services in China

Iron deficiency anemia (IDA) is a common hematologic disorder characterized by insufficient iron stores to support normal red blood cell production, resulting in microcytic, hypochromic anemia. It arises when iron demand exceeds supply—either due to inadequate dietary intake, impaired gastrointestinal absorption, chronic blood loss (e.g., menorrhagia, gastrointestinal bleeding from ulcers or colorectal lesions), or increased physiological requirements (e.g., pregnancy, infancy, adolescence). Pathogenically, iron depletion progresses through three stages: first, depletion of storage iron (ferritin ↓); second, reduction in serum iron and transferrin saturation with compensatory rise in total iron-binding capacity (TIBC); and third, frank anemia with low hemoglobin, low mean corpuscular volume (MCV), and low mean corpuscular hemoglobin (MCH). Without intervention, IDA impairs oxygen delivery, mitochondrial function, and cellular energetics—particularly affecting high-demand tissues like skeletal muscle, brain, and myocardium. Epidemiologically, IDA affects over 1.2 billion people globally, making it the most prevalent nutritional deficiency worldwide. Prevalence is highest among women of childbearing age (15–25% in non-pregnant, up to 40% in pregnant women), young children (20–30% under age 5), adolescents, and older adults with comorbid gastrointestinal disease. Key risk factors include vegetarian/vegan diets low in heme iron, chronic NSAID use, celiac disease, Helicobacter pylori infection, gastric bypass surgery, heavy menstrual bleeding, frequent blood donation, and undiagnosed gastrointestinal malignancy. Beyond hematologic parameters, IDA significantly diminishes quality of life: patients commonly report profound fatigue, reduced exercise tolerance, cognitive fog, irritability, pica (craving for ice, clay, or starch), restless legs syndrome, brittle nails (koilonychia), and pallor. Untreated, it contributes to impaired work productivity, school performance deficits in children, postpartum complications, heart failure exacerbation in susceptible individuals, and increased susceptibility to infections due to compromised immune cell function. Early diagnosis—via complete blood count, ferritin (gold-standard marker, though acute-phase reactant), serum iron, TIBC, and reticulocyte hemoglobin content (Ret-He)—is critical to guide targeted therapy and uncover underlying etiology, especially occult GI bleeding in adults over 50. Management must therefore integrate iron repletion with rigorous diagnostic evaluation to address root causes, ensuring sustainable recovery and preventing recurrence.

Iron deficiency anemia (IDA) is the most prevalent form of anemia worldwide, characterized by insufficient iron stores to support adequate hemoglobin synthesis, resulting in microcytic, hypochromic red blood cells and impaired oxygen delivery. In the Department of Hematology, management is stratified according to etiology, severity, comorbidities, and patient-specific factors—including age, gastrointestinal (GI) anatomy, absorption capacity, and tolerance to oral therapy. A comprehensive approach integrates conservative measures, pharmacologic intervention, targeted surgical evaluation, and long-term monitoring.

Conservative treatment forms the cornerstone of IDA management, particularly in mild-to-moderate cases without acute hemorrhage or high-risk features. It begins with rigorous diagnostic workup: complete blood count (CBC), peripheral blood smear, serum ferritin (the most specific indicator of iron stores), serum iron, total iron-binding capacity (TIBC), transferrin saturation (TSAT), and soluble transferrin receptor (sTfR). In adults—especially men and postmenopausal women—occult GI blood loss must be excluded via fecal immunochemical testing (FIT) and endoscopic evaluation (esophagogastroduodenoscopy and colonoscopy). Nutritional counseling is integral: patients are advised to increase dietary heme iron intake (e.g., lean red meat, poultry, fish) while avoiding concurrent ingestion of iron inhibitors such as calcium supplements, antacids, proton pump inhibitors (PPIs), tea, coffee, and phytate-rich foods. Vitamin C–rich foods (e.g., citrus fruits, bell peppers) should be consumed with iron-rich meals to enhance non-heme iron absorption. Lifestyle modifications include menstrual assessment in premenopausal women (e.g., evaluation for menorrhagia, uterine fibroids, or coagulopathies) and cessation of NSAID use where appropriate.

Pharmacologic therapy is initiated based on ferritin levels and clinical severity. Oral iron supplementation remains first-line for uncomplicated IDA. Ferrous sulfate (325 mg tablet = 65 mg elemental iron), ferrous fumarate (325 mg = 100 mg elemental iron), and ferrous gluconate (325 mg = 36 mg elemental iron) are commonly prescribed. Dosing regimens have evolved: recent evidence supports alternate-day dosing (e.g., 100 mg elemental iron every other morning on an empty stomach) to improve absorption and reduce gastrointestinal side effects (nausea, constipation, abdominal cramping) without compromising efficacy. Treatment duration extends beyond hemoglobin normalization—typically 3–6 months—to replenish hepatic and bone marrow iron stores, confirmed by follow-up ferritin >50 µg/L and TSAT >20%. Intravenous (IV) iron is indicated when oral therapy fails (e.g., persistent anemia despite 4–6 weeks of adherence), intolerance, malabsorption syndromes (e.g., celiac disease, post-bariatric surgery), chronic inflammatory conditions (where hepcidin-mediated blockade limits oral absorption), or severe anemia (Hb <9 g/dL) with symptomatic burden (e.g., angina, heart failure, profound fatigue). Modern IV formulations—including ferric carboxymaltose (FCM), ferric derisomaltose (FDI), and low-molecular-weight iron dextran—are administered as single or split infusions under hemodynamic monitoring. FCM allows rapid repletion (up to 1000 mg in ≤15 minutes) and has demonstrated superior safety over older dextran-based products, with minimal risk of anaphylaxis (<0.1%).

Surgical intervention is not a primary treatment for IDA itself but is essential when IDA serves as a sentinel sign of underlying structural pathology. In the hematology setting, close collaboration with gastroenterology, gynecology, and general surgery is mandatory. Indications for surgery include: (1) endoscopically confirmed bleeding lesions refractory to medical therapy (e.g., angiodysplasia amenable to argon plasma coagulation or endoscopic band ligation); (2) resectable GI malignancies (e.g., colon cancer, gastric adenocarcinoma); (3) surgically correctable gynecologic causes (e.g., hysterectomy for refractory menorrhagia due to large fibroids or adenomyosis); and (4) vascular malformations or hereditary hemorrhagic telangiectasia (HHT)-related epistaxis requiring septodermoplasty or laser ablation. Laparoscopic and robotic-assisted techniques minimize perioperative morbidity and accelerate recovery. Preoperative optimization includes IV iron repletion to avoid unnecessary allogeneic transfusion, reduce postoperative complications, and shorten hospital stay.

Treatment advantages in China reflect robust infrastructure, innovation, and integration. Chinese hematology centers—particularly tier-3 hospitals in Beijing, Shanghai, Guangzhou, and Chengdu—offer rapid access to high-sensitivity ferritin assays, mass spectrometry–based iron metabolism panels, and AI-enhanced endoscopic detection of subtle mucosal bleeding. Domestic production of high-purity IV iron (e.g., CosmoFer®-equivalent ferric carboxymaltose manufactured by Jiangsu Hengrui) ensures cost-effectiveness and supply chain resilience. National Clinical Guidelines for Iron Deficiency Anemia (2023 edition) standardize diagnostic thresholds (e.g., ferritin <30 µg/L diagnostic in adults; <15 µg/L in children) and endorse early IV iron in high-risk populations. Telehematology platforms facilitate longitudinal monitoring, medication adherence tracking, and remote nutritional coaching—critical for rural patients. Moreover, China’s large-scale epidemiologic databases (e.g., China Kadoorie Biobank) inform precision risk stratification, identifying genetic variants (e.g., TMPRSS6 polymorphisms) associated with iron-refractory IDA.

Recovery advice emphasizes sustainability and prevention. Patients should undergo repeat CBC and ferritin at 4 weeks after initiating therapy, then every 3 months until stores normalize. Lifelong surveillance is recommended for those with chronic blood loss (e.g., hereditary hemorrhagic telangiectasia, inflammatory bowel disease) or malabsorption. Dietary education must be culturally tailored: encouraging traditional iron-rich foods like pig liver, duck blood curd, black fungus, and fortified soy sauce, while advising moderation of tea consumption during meals. Women of childbearing age should receive preconception counseling regarding iron prophylaxis (e.g., 30–60 mg elemental iron daily starting 3 months prior to conception). All patients must understand that symptom resolution (e.g., improved energy, cognition, exercise tolerance) often precedes laboratory normalization by 2–4 weeks—and that premature discontinuation of therapy risks relapse. Finally, psychosocial support is vital: chronic IDA correlates with depression, reduced quality of life, and workplace impairment; multidisciplinary rehabilitation—including graded aerobic activity and cognitive behavioral strategies—improves functional outcomes. With systematic, patient-centered care, >95% of IDA cases achieve full hematologic recovery within 6 months, underscoring the importance of timely diagnosis, individualized therapy, and proactive long-term stewardship.